Aislamiento y caracterización de una cepa temprana de SARS-CoV-2 durante la epidemia de 2020 en Medellín, Colombia

Díaz, Francisco J.; Aguilar-Jiménez, Wbeimar; Flórez-Álvarez, Lizdany; Valencia, Gladys Lucía Acosta; Laiton‐Donato, Katherine; Franco-Muñoz, Carlos; Álvarez-Díaz, Diego A.; Mercado, Marcela; Rugeles, Marı́a Teresa

doi:10.7705/biomedica.5834

Cited by 19 publications

(18 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Cultures were maintained at 37°C, with 5% CO 2 . Infections were done with a viral stock produced from a Colombian isolate of SARS-CoV-2 (hCoV-19/Colombia/ANT-UdeA-200325-01/2020) [ 25 ].…”

Section: Methodsmentioning

confidence: 99%

The Hydroalcoholic Extract of Uncaria tomentosa (Cat’s Claw) Inhibits the Infection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) In Vitro

Yepes-Pérez

Herrera-Calderón

Oliveros

et al. 2021

Evidence-Based Complementary and Alternative Medicine

Self Cite

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID-19) has become a serious problem for public health since it was identified in the province of Wuhan (China) and spread around the world producing high mortality rates and economic losses. Nowadays, the WHO recognizes traditional, complementary, and alternative medicine for treating COVID-19 symptoms. Therefore, we investigated the antiviral potential of the hydroalcoholic extract of Uncaria tomentosa stem bark from Peru against SARS-CoV-2 in vitro. The antiviral activity of U. tomentosa against SARS-CoV-2 in vitro was assessed in Vero E6 cells using cytopathic effect (CPE) and plaque reduction assay. After 48 h of treatment, U. tomentosa showed an inhibition of 92.7% of SARS-CoV-2 at 25.0 μg/mL ( p < 0.0001 ) by plaque reduction assay on Vero E6 cells. In addition, U. tomentosa induced a reduction of 98.6% ( p = 0.02 ) and 92.7% ( p = 0.03 ) in the CPE caused by SARS-CoV-2 on Vero E6 cells at 25 μg/mL and 12.5 μg/mL, respectively. The EC50 calculated for the U. tomentosa extract by plaque reduction assay was 6.6 μg/mL (4.89–8.85 μg/mL) for a selectivity index of 4.1. The EC50 calculated for the U. tomentosa extract by TCID50 assay was 2.57 μg/mL (1.05–3.75 μg/mL) for a selectivity index of 10.54. These results showed that U. tomentosa, known as cat's claw, has an antiviral effect against SARS-CoV-2, which was observed as a reduction in the viral titer and CPE after 48 h of treatment on Vero E6 cells. Therefore, we hypothesized that U. tomentosa stem bark could be promising in the development of new therapeutic strategies against SARS-CoV-2.

show abstract

Section: Methodsmentioning

confidence: 99%

The Hydroalcoholic Extract of Uncaria tomentosa (Cat’s Claw) Inhibits the Infection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) In Vitro

Yepes-Pérez

Herrera-Calderón

Oliveros

et al. 2021

Evidence-Based Complementary and Alternative Medicine

Self Cite

View full text Add to dashboard Cite

show abstract

“…The incubation conditions were 37°C, 5% CO 2 atmosphere, and relative humidity. The cells were infected with a viral stock produced from a Colombian isolate of SARS-CoV-2 (hCoV-19/Colombia/ANT-UdeA-200325-01/2020) [47]. The virus was propagated on Vero E6 cells.…”

Section: Methodsmentioning

confidence: 99%

Atorvastatin effectively inhibits late replicative cycle steps of SARS-CoV-2in vitro

Flórez-Álvarez

Zapata

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

Introduction: SARS-CoV-2 has caused a pandemic of historic proportions and continues to spread worldwide. Currently, there is no effective therapy against this virus. This article evaluated the in vitro antiviral effect of Atorvastatin against SARS-CoV-2 and also identified the interaction affinity between Atorvastatin and three SARS-CoV-2 proteins, using in silico structure-based molecular docking approach. Materials and methods: The antiviral activity of Atorvastatin against SARS-CoV-2 was evaluated by three different treatment strategies using a clinical isolate of SARS-CoV-2. The interaction of Atorvastatin with Spike, RNA-dependent RNA polymerase (RdRp) and 3C-like protease (3CLpro) was evaluated by molecular docking. Results: Atorvastatin showed anti-SARS-CoV-2 activity of 79%, 54.8%, 22.6% and 25% at 31.2, 15.6, 7.9, and 3.9 µM, respectively, by pre-post-treatment strategy. In addition, atorvastatin demonstrated an antiviral effect of 26.9% at 31.2 µM by pre-infection treatment. This compound also inhibited SARS-CoV-2 in 66.9%, 75%, 27.9% and 29.2% at concentrations of 31.2, 15.6, 7.9, and 3.9 µM, respectively, by post-infection treatment. The interaction of atorvastatin with SARS-CoV-2 Spike, RdRp and 3CL protease yielded a binding affinity of -8.5 Kcal/mol, -6.2 Kcal/mol, and -7.5 Kcal/mol, respectively. Conclusion: Our study demonstrated the in vitro anti-SARS-CoV-2 activity of Atorvastatin, mainly against the late steps of the viral replicative cycle. A favorable binding affinity with viral proteins by bioinformatics methods was also shown. Due to its low cost, availability, well-established safety and tolerability, and the extensive clinical experience of atorvastatin, it could prove valuable in reducing morbidity and mortality from COVID-19.

show abstract

“…PBMCs were thawed and left in culture with RPMI (Sigma-Aldrich) supplemented with 10% fetal bovine serum (FBS) (Sigma-Aldrich) for 24 h before the experiments. K562 cells were used as targets 20 . Prior to culturing, 1×10 6 K562 cells were stained with 0.1 mM eFluor™ 670 (Thermo Fisher Scientific) in PBS for 10 min at 37°C.…”

Section: Methodsmentioning

confidence: 99%

Immune characterization of a Colombian family cluster with SARS-CoV-2 infection

et al. 2021

Self Cite

View full text Add to dashboard Cite

Introduction: Immunological markers have been described during COVID-19 and persist after recovery. Those immune alterations are associated with clinical features among SARS-CoV-2 infected individuals. Although, studies reporting a comprehensive analysis of these immune alterations are still limited. Objective: To evaluate the production of pro-inflammatory cytokines, antibody response, and phenotype and function of NK cells and T cells in a Colombian familiar cluster of SARS-CoV-2 infection. Materials and methods: Proinflammatory cytokines were evaluated by RT-PCR and ELISA. Frequency, phenotype and function of NK cells (cocultures with K562 cells) and T-cells (stimulated with Spike/RdRp peptides) were assessed by flow cytometry; anti-SARS-CoV-2 antibodies were determined by indirect immunofluorescence and plaque reduction neutralization assay. Results: During COVID-19, we observed a high pro-inflammatory cytokine production and reduced CD56bright NK cells and cytotoxic response. Compared with healthy controls, infected individuals had a higher frequency of dysfunctional CD8+ T cells CD38+HLA-DR-. During the acute phase, CD8+ T cells stimulated with viral peptides exhibited a monofunctional response characterized by a high IL-10 production. Nevertheless, during recovery, a bifunctional response was observed, characterized by the co-expression of CD107a and Granzyme B or Perforin. Conclusion: Although pro-inflammatory response is a hallmark of SARS-CoV-2 infection, other phenotypic and functional alterations in NK cells and CD8+ T cells could be associated with the outcome of COVID-19. However, additional studies are required to understand these alterations and, to guide future immunotherapy strategies.

show abstract

Aislamiento y caracterización de una cepa temprana de SARS-CoV-2 durante la epidemia de 2020 en Medellín, Colombia

Cited by 19 publications

References 16 publications

The Hydroalcoholic Extract of Uncaria tomentosa (Cat’s Claw) Inhibits the Infection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) In Vitro

The Hydroalcoholic Extract of Uncaria tomentosa (Cat’s Claw) Inhibits the Infection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) In Vitro

Atorvastatin effectively inhibits late replicative cycle steps of SARS-CoV-2in vitro

Immune characterization of a Colombian family cluster with SARS-CoV-2 infection

Contact Info

Product

Resources

About